Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate CancerShusuke Akamatsu, Osamu Ogawa, Keiji Ogura et al.|European Urology Oncology|2018Cited by 55
Differential prognostic factors in low‐ and high‐burden de novo metastatic hormone‐sensitive prostate cancer patientsMasaki Shiota, Naoki Terada, Toshihiro Saito et al.|Cancer Science|2020Cited by 48
Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitorsWataru Fukuokaya, Shin Egawa, Takahiro Kimura et al.|Urologic Oncology Seminars and Original Investigations|2022Cited by 24
Potential effectiveness of local radiotherapy for extending survival and reducing symptomatic local events in patients with de novo metastatic prostate cancerNaoki Terada, Takashi Mizowaki, Toshihiro Saito et al.|BJUI Compass|2020Cited by 19
Novel metastatic burden‐stratified risk model in de novo metastatic hormone‐sensitive prostate cancerMasaki Shiota, Naoki Terada, Hiroshi Kitamura et al.|Cancer Science|2021Cited by 15